These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 15549010)

  • 1. Management of patients who have relapses in multiple sclerosis.
    Williams G
    Br J Nurs; 2004 Sep 23-Oct 13; 13(17):1012-6. PubMed ID: 15549010
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Treatment of relapses of multiple sclerosis (a review)].
    Brkovich RR; Totolian NA; Sokolov AIu; Ignatov IuD; Skoromets AA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(10 Pt 2):69-77. PubMed ID: 24416811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The natural history of relapses in multiple sclerosis.
    Vollmer T
    J Neurol Sci; 2007 May; 256 Suppl 1():S5-13. PubMed ID: 17346747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of Multiple Sclerosis Relapses.
    Repovic P
    Continuum (Minneap Minn); 2019 Jun; 25(3):655-669. PubMed ID: 31162310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relapse prevalence, symptoms, and health care engagement: patient insights from the Multiple Sclerosis in America 2017 survey.
    Nazareth TA; Rava AR; Polyakov JL; Banfe EN; Waltrip Ii RW; Zerkowski KB; Herbert LB
    Mult Scler Relat Disord; 2018 Nov; 26():219-234. PubMed ID: 30368080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study.
    Burt RK; Loh Y; Cohen B; Stefoski D; Balabanov R; Katsamakis G; Oyama Y; Russell EJ; Stern J; Muraro P; Rose J; Testori A; Bucha J; Jovanovic B; Milanetti F; Storek J; Voltarelli JC; Burns WH
    Lancet Neurol; 2009 Mar; 8(3):244-53. PubMed ID: 19186105
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Differential influence of immune therapy on relapses and progression in multiple sclerosis: interpretation and therapeutic consequences].
    Kornhuber ME; Presek P; Zierz S
    Fortschr Neurol Psychiatr; 2005 Mar; 73(3):143-9. PubMed ID: 15747223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cervical disk pathology in patients with multiple sclerosis: two case reports.
    Mullen AE; Wilmarth MA; Lowe S
    Phys Ther; 2012 Aug; 92(8):1055-64. PubMed ID: 22517783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recommendations for the management of multiple sclerosis relapses.
    Laplaud D; Bodiguel E; Bensa C; Blanc F; Brassat D; Magy L; Ouallet JC; Zephir H; De Seze J;
    Rev Neurol (Paris); 2012 May; 168(5):425-33. PubMed ID: 22555010
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [General practitioners' approach to relapsing multiple sclerosis].
    Mackowiak A; Jamart V; Donze C; Hautecoeur P;
    Rev Neurol (Paris); 2003 Feb; 159(2):196-8. PubMed ID: 12660572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relapse management in multiple sclerosis.
    Thrower BW
    Neurologist; 2009 Jan; 15(1):1-5. PubMed ID: 19131851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of relapsing-remitting multiple sclerosis: current approaches and unmet needs.
    Miller AE; Rhoades RW
    Curr Opin Neurol; 2012 Feb; 25 Suppl():S4-10. PubMed ID: 22398662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Natural history of multiple sclerosis: a unifying concept.
    Confavreux C; Vukusic S
    Brain; 2006 Mar; 129(Pt 3):606-16. PubMed ID: 16415308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial.
    Sorensen PS; Mellgren SI; Svenningsson A; Elovaara I; Frederiksen JL; Beiske AG; Myhr KM; Søgaard LV; Olsen IC; Sandberg-Wollheim M
    Lancet Neurol; 2009 Jun; 8(6):519-29. PubMed ID: 19409854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple sclerosis relapses: a multivariable analysis of residual disability determinants.
    Vercellino M; Romagnolo A; Mattioda A; Masera S; Piacentino C; Merola A; Chiò A; Mutani R; Cavalla P
    Acta Neurol Scand; 2009 Feb; 119(2):126-30. PubMed ID: 18684216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The psychosocial effect of multiple sclerosis: the impact of relapses.
    Halper J
    J Neurol Sci; 2007 May; 256 Suppl 1():S34-8. PubMed ID: 17350047
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient education program to enhance decision autonomy in multiple sclerosis relapse management: a randomized-controlled trial.
    Köpke S; Kasper J; Mühlhauser I; Nübling M; Heesen C
    Mult Scler; 2009 Jan; 15(1):96-104. PubMed ID: 18845657
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of relapse rate in MS clinical trials.
    Held U; Heigenhauser L; Shang C; Kappos L; Polman C;
    Neurology; 2005 Dec; 65(11):1769-73. PubMed ID: 16344520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The incomplete nature of multiple sclerosis relapse resolution.
    Lublin FD
    J Neurol Sci; 2007 May; 256 Suppl 1():S14-8. PubMed ID: 17337274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Steroid treatment for relapses in multiple sclerosis - the evidence urges shared decision-making.
    Köpke S; Heesen C; Kasper J; Mühlhauser I
    Acta Neurol Scand; 2004 Jul; 110(1):1-5. PubMed ID: 15180800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.